Pre-Exposure Prophylaxis (prep)

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Pre-Exposure Prophylaxis (PrEP) is an early-stage landscape with 0 programs across 1 company. The most active players are Gilead.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Gilead

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed11 · 65%

Unknown status2 · 12%

Active, not recruiting2 · 12%

Recruiting1 · 6%

Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

Recruiting·DDesmond Tutu HIV Foundation·N/A·NCT06807736·1,800 enrolled

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

Active, not recruiting·UUniversity of Witwatersrand, South Africa·Phase 3·NCT06138600·200 enrolled

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Active, not recruiting· Gilead logo

Gilead·Phase 2·NCT06513312·268 enrolled

ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.

Not yet recruiting·DDesmond Tutu HIV Foundation·N/A·NCT07390409·3,700 enrolled

Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)

Completed·AANRS, Emerging Infectious Diseases·Phase 3·NCT04597424·556 enrolled

Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women

Completed·JJohns Hopkins University·Phase 1·NCT03060785·16 enrolled

Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women

Completed·UUniversity of California, Los Angeles·N/A·NCT03902418·1,195 enrolled

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

Completed·JJohns Hopkins University·Phase 1·NCT04760691·13 enrolled

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

Completed·IInternational AIDS Vaccine Initiative·Phase 1/2·NCT00931346·72 enrolled

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

Completed·HHIV Prevention Trials Network·Phase 2·NCT01327651·622 enrolled

Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women

Completed·UUniversity of California, Los Angeles·Phase 4·NCT02584140·136 enrolled

Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India

Completed·UUniversity of Manitoba·Phase 1·NCT02148094·1,325 enrolled

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

Completed·IInternational AIDS Vaccine Initiative·Phase 1/2·NCT00971230·72 enrolled

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT02022657·52 enrolled

eSTEP: An Integrated mHealth Intervention to Engage High-risk Individuals Along the Full PrEP Care Continuum

Completed·San Diego State University·Preclinical·NCT06159582·113 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)